vs
ASCENT INDUSTRIES CO.（ACNT）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是ASCENT INDUSTRIES CO.的1.6倍（$19.6M vs $11.9M），ASCENT INDUSTRIES CO.净利率更高（-8.8% vs -177.4%，领先168.6%），ASCENT INDUSTRIES CO.同比增速更快（13.3% vs -11.5%），ASCENT INDUSTRIES CO.自由现金流更多（$-196.0K vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -34.9%）
阿森特工业（股票代码ACNT）前身为拆分自探索控股公司的独立上市媒体企业阿森特传媒，后转型为公开上市控股公司，核心子公司为莫尼特罗尼克斯，主营依托子公司开展安防相关业务运营。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ACNT vs LAB — 直观对比
营收规模更大
LAB
是对方的1.6倍
$11.9M
营收增速更快
ACNT
高出24.8%
-11.5%
净利率更高
ACNT
高出168.6%
-177.4%
自由现金流更多
ACNT
多$22.9M
$-23.1M
两年增速更快
LAB
近两年复合增速
-34.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.9M | $19.6M |
| 净利润 | $-1.0M | $-34.7M |
| 毛利率 | 14.6% | 48.5% |
| 营业利润率 | -21.0% | -168.5% |
| 净利率 | -8.8% | -177.4% |
| 营收同比 | 13.3% | -11.5% |
| 净利润同比 | -1.2% | -28.8% |
| 每股收益（稀释后） | $-0.11 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACNTLAB
| Q4 25 | $11.9M | — | ||
| Q3 25 | $19.7M | $19.6M | ||
| Q2 25 | $18.7M | $21.8M | ||
| Q1 25 | $24.7M | $40.8M | ||
| Q4 24 | $10.5M | — | ||
| Q3 24 | $20.9M | $22.1M | ||
| Q2 24 | $21.5M | $22.5M | ||
| Q1 24 | $28.0M | $45.5M |
净利润ACNTLAB
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-2.1M | $-34.7M | ||
| Q2 25 | $6.3M | $-33.5M | ||
| Q1 25 | $-2.3M | $-26.0M | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $-6.2M | $-26.9M | ||
| Q2 24 | $-926.0K | $-45.7M | ||
| Q1 24 | $-5.5M | $-32.2M |
毛利率ACNTLAB
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | 48.5% | ||
| Q2 25 | 26.1% | 48.8% | ||
| Q1 25 | 19.3% | 48.4% | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 14.4% | 54.9% | ||
| Q2 24 | 13.1% | 46.1% | ||
| Q1 24 | 8.3% | 53.1% |
营业利润率ACNTLAB
| Q4 25 | -21.0% | — | ||
| Q3 25 | -4.1% | -168.5% | ||
| Q2 25 | -14.4% | -118.1% | ||
| Q1 25 | -4.2% | -80.8% | ||
| Q4 24 | -25.4% | — | ||
| Q3 24 | -9.4% | -120.9% | ||
| Q2 24 | -8.6% | -134.5% | ||
| Q1 24 | -15.5% | -132.2% |
净利率ACNTLAB
| Q4 25 | -8.8% | — | ||
| Q3 25 | -10.6% | -177.4% | ||
| Q2 25 | 33.7% | -153.7% | ||
| Q1 25 | -9.3% | -63.8% | ||
| Q4 24 | -9.8% | — | ||
| Q3 24 | -29.5% | -122.0% | ||
| Q2 24 | -4.3% | -203.3% | ||
| Q1 24 | -19.7% | -70.6% |
每股收益（稀释后）ACNTLAB
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.22 | $-0.09 | ||
| Q2 25 | $0.65 | $-0.09 | ||
| Q1 25 | $-0.23 | $-0.07 | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.61 | $-0.07 | ||
| Q2 24 | $-0.09 | $-0.12 | ||
| Q1 24 | $-0.54 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.6M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $87.0M | $399.7M |
| 总资产 | $111.9M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACNTLAB
| Q4 25 | $57.6M | — | ||
| Q3 25 | $58.0M | $129.4M | ||
| Q2 25 | $60.5M | $158.6M | ||
| Q1 25 | $14.3M | $150.9M | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $8.5M | $210.6M | ||
| Q2 24 | $3.6M | $269.8M | ||
| Q1 24 | $1.3M | $287.1M |
总债务ACNTLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益ACNTLAB
| Q4 25 | $87.0M | — | ||
| Q3 25 | $87.1M | $399.7M | ||
| Q2 25 | $89.7M | $424.5M | ||
| Q1 25 | $91.2M | $454.6M | ||
| Q4 24 | $93.5M | — | ||
| Q3 24 | $94.7M | $489.3M | ||
| Q2 24 | $101.0M | $510.3M | ||
| Q1 24 | $102.0M | $577.3M |
总资产ACNTLAB
| Q4 25 | $111.9M | — | ||
| Q3 25 | $119.9M | $539.6M | ||
| Q2 25 | $122.6M | $557.0M | ||
| Q1 25 | $152.5M | $579.6M | ||
| Q4 24 | $147.3M | — | ||
| Q3 24 | $148.6M | $681.5M | ||
| Q2 24 | $158.2M | $708.7M | ||
| Q1 24 | $161.0M | $777.7M |
负债/权益比ACNTLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $266.0K | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-196.0K | $-23.1M |
| 自由现金流率自由现金流/营收 | -1.7% | -118.1% |
| 资本支出强度资本支出/营收 | 3.9% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.1M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流ACNTLAB
| Q4 25 | $266.0K | — | ||
| Q3 25 | $1.3M | $-22.2M | ||
| Q2 25 | $-1.4M | $-20.7M | ||
| Q1 25 | $-700.0K | $-30.3M | ||
| Q4 24 | $8.8M | — | ||
| Q3 24 | $3.4M | $-27.9M | ||
| Q2 24 | $2.2M | $-39.0M | ||
| Q1 24 | $263.0K | $-62.5M |
自由现金流ACNTLAB
| Q4 25 | $-196.0K | — | ||
| Q3 25 | $695.0K | $-23.1M | ||
| Q2 25 | $-1.5M | $-22.6M | ||
| Q1 25 | $-1.0M | $-35.3M | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $3.1M | $-30.1M | ||
| Q2 24 | $1.9M | $-41.0M | ||
| Q1 24 | $25.0K | $-63.3M |
自由现金流率ACNTLAB
| Q4 25 | -1.7% | — | ||
| Q3 25 | 3.5% | -118.1% | ||
| Q2 25 | -8.3% | -103.6% | ||
| Q1 25 | -4.1% | -86.6% | ||
| Q4 24 | 80.6% | — | ||
| Q3 24 | 15.1% | -136.4% | ||
| Q2 24 | 9.1% | -182.2% | ||
| Q1 24 | 0.1% | -138.9% |
资本支出强度ACNTLAB
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.1% | 4.5% | ||
| Q2 25 | 0.8% | 8.7% | ||
| Q1 25 | 1.3% | 12.4% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.3% | 10.2% | ||
| Q2 24 | 1.0% | 8.6% | ||
| Q1 24 | 0.9% | 1.7% |
现金转化率ACNTLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
